Arcus Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	127	206	148	173.62	58.14	71.27	98.63	65.36
Short-Term Investments	632	803	351	555.23	130.33	185.48	77.28	33.74
Cash & Cash Equivalents	759	1,009	499	728.85	188.47	256.75	175.91	99.1
Cash Growth	-24.78%	102.20%	-31.54%	286.71%	-26.59%	45.96%	77.51%	-
Receivables	38	39	745	1.05	0.13	0.08	0.03	0.41
Other Current Assets	34	19	18	5.92	4.1	2.12	0.94	0.19
Total Current Assets	831	1,067	1,262	735.82	192.71	258.95	176.87	99.69
Property, Plant & Equipment	51	35	32	23.59	9.33	11.11	11.23	8.61
Long-Term Investments	107	129	182	6.44	0	4.38	0.68	1
Other Long-Term Assets	106	114	116	6.45	1.08	0.49	1.71	0.4
Total Long-Term Assets	264	278	330	36.48	10.41	15.98	13.62	10.01
Total Assets	1,095	1,345	1,592	772.29	203.11	274.93	190.49	109.7
Accounts Payable	17	20	10	15.68	4.7	3.1	3.82	3.87
Deferred Revenue	398	452	564	207.1	19.02	23.23	23.59	0
Other Current Liabilities	-231	-279	-408	-101.12	-1.02	-9.4	-14.68	1.68
Total Current Liabilities	184	193	166	121.67	22.71	16.94	12.73	5.55
Long-Term Debt	0	0	0	15.24	0	0	0	0
Other Long-Term Liabilities	449	495	584	133.08	16.56	23.05	23.89	4.7
Total Long-Term Liabilities	449	495	584	148.32	16.56	23.05	23.89	4.7
Total Liabilities	633	688	750	269.99	39.27	39.98	36.62	10.24
Total Debt	0	0	0	15.24	0	0	0	0
Retained Earnings	-849	-542	-275	-328.18	-205.33	-122.83	-73.23	-20.15
Comprehensive Income	0	-7	-1	0.04	0.06	-0.11	-0.04	-0.03
Shareholders' Equity	462	657	842	502.3	163.84	234.94	-72.33	-19.99
Net Cash / Debt	759	1,009	499	713.61	188.47	256.75	175.91	99.1
Net Cash / Debt Growth	-24.78%	102.20%	-30.07%	278.63%	-26.59%	45.96%	77.51%	-
Net Cash Per Share	10.26	14.01	6.74	13.02	4.30	7.42	96.21	114.70
Working Capital	647	874	1,096	614.15	170	242.01	164.14	94.15
Book Value Per Share	6.24	9.13	12.15	9.17	3.74	6.79	-39.56	-23.14

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).